Unique ID issued by UMIN | UMIN000011191 |
---|---|
Receipt number | R000013114 |
Scientific Title | Efficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trial |
Date of disclosure of the study information | 2013/07/16 |
Last modified on | 2017/01/27 11:59:15 |
Efficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trial
A randomized controlled trial of escitalopram versus paroxetine-CR in major depressive disorder
Efficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trial
A randomized controlled trial of escitalopram versus paroxetine-CR in major depressive disorder
Japan |
major depressive disorder
Psychiatry |
Others
NO
To compare the therapeutic efficacy and tolerability of escitalopram and paroxetine in patients with major depressive disorder
PK,PD
Exploratory
Explanatory
Not applicable
The Hamilton Rating Scale for Depression
Remission rate
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Escitalopram
Paroxetine-CR
20 | years-old | <= |
75 | years-old | >= |
Male and Female
Patients (inpatients and outpatients), diagnosed with major depressive disorder (according to the DSM-IV-TR criteria)
Patients with HAM-D17 total score 20 or more
Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder.
Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria
Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days)
Patients taking pimozide
Patients with allergies to escitalopram, citalopram and paroxetine
Patients with QT interval prolongation
Patients treated with ECT within the previous 6 months
Patients having severe physical disease
Patients who are pregnant or may become pregnant
Patients at significant risk of suicide (having a score >3 on HAM-D item 11)
Patients who had made suicide attempt within the past year
200
1st name | |
Middle name | |
Last name | Nakao Iwata |
Fujita Health University School of Medicine
Department of Psychiatry
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan
0562939250
1st name | |
Middle name | |
Last name | Taro Kishi |
Fujita Health University School of Medicine
Department of Psychiatry
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi. 470-1192. Japan
0562939250
tarok@fujita-hu.ac.jp
Department of Psychiatry, Fujita Health University School of Medicine
Health and Labor Sciences Research Grant
Other
The Okehazama Hospital
The Jindai Hospital
The St. Cross Hospital
The Toyota Memorial Hospital
NO
2013 | Year | 07 | Month | 16 | Day |
Published
https://www.dovepress.com/escitalopram-versus-paroxetine-controlled-release-in-major-depressive--pee
Completed
2013 | Year | 07 | Month | 16 | Day |
2013 | Year | 07 | Month | 16 | Day |
2016 | Year | 08 | Month | 16 | Day |
2013 | Year | 07 | Month | 16 | Day |
2017 | Year | 01 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013114
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |